Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 7/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 9/20 | 0.41 |
| ▸ | ABCC1 | P33527 | 4/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.41 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.41 |
| ▸ | HTR1A | P08908 | 2/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | DRD3 | P35462 | 2/20 | 0.41 |
| ▸ | SCN1A | P35498 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7317596 | 0.77 | CYP3A4 (0.43) | CYP3A4ABCB1ABCC1KCNH2TSHR | |
| SCHEMBL7265656 | 0.76 | ABCB1 (0.45) | CYP3A4ABCB1ABCC1KCNH2TSHR | |
| SCHEMBL9492143 | 0.75 | SIGMAR1 (0.67) | CYP3A4ABCB1ABCC1KCNH2TSHR | |
| SCHEMBL10452711 | 0.75 | SIGMAR1 (0.67) | CYP3A4ABCB1ABCC1KCNH2TSHR | |
| SCHEMBL10452583 | 0.74 | SIGMAR1 (0.63) | CYP3A4ABCB1ABCC1KCNH2TSHR | |
| SCHEMBL9490429 | 0.74 | SIGMAR1 (0.63) | CYP3A4ABCB1ABCC1KCNH2TSHR | |
| SCHEMBL9490479 | 0.74 | SIGMAR1 (0.76) | CYP3A4ABCB1ABCC1KCNH2TSHR | |
| SCHEMBL9492153 | 0.71 | ABCB1 (0.60) | CYP3A4ABCB1ABCC1KCNH2TSHR | |
| SCHEMBL9492147 | 0.71 | ABCB1 (0.60) | CYP3A4ABCB1ABCC1KCNH2TSHR | |
| SCHEMBL9490484 | 0.70 | ABCB1 (0.57) | CYP3A4ABCB1ABCC1KCNH2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514454-B2 | Piperidin-2,6-dione pamoate salts and their use for the treatment of stress-related affective disorders | PRESTWICK PHARMACEUTICALS, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| EP-1420788-B1 | NOVEL PIPERIDIN-2,6-DIONE BISULPHATE SALTS AND THEIR USE FOR THE TREATMENT OF STRESS-RELATED AFFECTIVE DISORDERS | PRESTWICK PHARMACEUTICALS INC (US) | 2006-12-13 | — | — | EP | disclosed |
| EP-1539160-B1 | PIPERIDIN-2,6-DIONE PAMOATE SALTS AND THEIR USE FOR THE TREATMENT OF STRESS-RELATED AFFECTIVE DISORDERS | PRESTWICK PHARMACEUTICALS INC (US) | 2006-06-21 | — | — | EP | disclosed |
| US-20060025443-A1 | Piperidin-2,6-dione pamoate salts and their use for the treatment of stress-related affective disorders | BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC) (HU) | 2006-02-02 | — | — | US | disclosed |
| EP-1539160-A1 | PIPERIDIN-2,6-DIONE PAMOATE SALTS AND THEIR USE FOR THE TREATMENT OF STRESS-RELATED AFFECTIVE DISORDERS | Prestwick Pharmaceuticals, Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040249159-A1 | Novel piperidin-2,6-dione disulphate salts and their use for the treatment of stress related affective disorders | BAUSCH & LOMB INCORPORATED | 2004-12-09 | — | — | US | disclosed |
| EP-1420788-A1 | NOVEL PIPERIDIN-2,6-DIONE BISULPHATE SALTS AND THEIR USE FOR THE TREATMENT OF STRESS-RELATED AFFECTIVE DISORDERS | Prestwick Pharmaceuticals, Inc. (US) | 2004-05-26 | — | — | EP | disclosed |
| WO-2004017970-A1 | PIPERIDIN-2,6-DIONE PAMOATE SALTS AND THEIR USE FOR THE TREATMENT OF STRESS-RELATED AFFECTIVE DISORDERS | PRESTWICK PHARMACEUTICALS, INC. (US) | 2004-03-04 | — | — | WO | disclosed |
| WO-2003020275-A1 | NOVEL PIPERIDIN-2,6-DIONE BISULPHATE SALTS AND THEIR USE FOR THE TREATMENT OF STRESS-RELATED AFFECTIVE DISORDERS | PRESTWICK PHARMACEUTICALS, INC. (US) | 2003-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040249159-A1 | Novel piperidin-2,6-dione disulphate salts and their use for the treatment of stress related affective disorders | EGLN2, EGLN3, HTR2C | CYP3A4 1964/4885ABCB1 2726/4885ABCC1 2857/4885 |
| US-20060025443-A1 | Piperidin-2,6-dione pamoate salts and their use for the treatment of stress-related affective disorders | PAM, HTR3B, HTR5A | CYP3A4 1260/4885ABCB1 2863/4885ABCC1 3288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.